Annual Report 2003 Aventis - Sanofi

Financial Highlights
Net Sales
(in e million)
Activity Variance (1)
EBITA (2) Margin
(in % of sales)
Net Income
(in e million)
Research and
Development
(in e million)
Capital
Expenditures
(in e million)
2003
16 791
27.4
2 444
2 863
773
2002
17 591
25.6
2 081
3 141
864
Total Variance
(1) Excluding currency translation effects
(2) Unaudited non-GAAP measure we define as operating income before goodwill
amortization plus equity in earnings of affiliated companies
The above figures refer to the Aventis core
business (prescription drugs, human vaccines,
our 50 % equity stake in the Merial animal
health joint venture, and corporate activities).
This report is being provided for information
purposes only. Aventis prepares a legally
binding annual report in French known as the
“Document de Référence” prior to its Annual
General Meeting as well as an annual report
in English on Form 20-F pursuant to the U.S.
Securities Exchange Act of 1934.
-4.5 %
5.9 %
+1.8 p.p.
17.5 %
-9 %
-11 %
Key Aventis Share Data
Basic Earnings per Share (in e)
Basic Earnings per Share
before Goodwill Amortization
(in e)
Number of shares
as of December 31
Per share information (in e)
Dividend
Price-earnings ratio
Stockholders’ equity
(in e billion)
Year-end share price
High
Low
Market capitalization
as of December 31 (in e billion)
Average daily trading volume
(number of shares)
Paris
New York
Frankfurt
2003
3.11
3.72
802 292 807
0.82
16.85
10.4
52.40
54.55
37.50
42.04
3 512 837
304 342
52 640
2002
2.62
3.31
799 474 490
0.70
19.77
11.3
51.80
85.95
47.60
41.41
2 920 038
260 116
64 766